November 9-11, 2020 | Virtual Conference


Bing Li, PhD


Dr. Bing V. Li is the director for Office of Bioequivalence. Bing has been the Director of the Division of Bioequivalence I (DBI) in OB since 2015. She started her regulatory science career in DBI in 2004. Bing is a pharmacologist and an expert in the bioequivalence of aerosolized drug products, as well as an editor and author for the book FDA Bioequivalence Standards. Prior to joining FDA, her work as a research investigator led to her receiving the New Jersey State Edison Patent Award in the pharmaceutical category for an invention related to the treatment of Type 2 diabetes. Bing received her PhD in Pharmaceutical Sciences from the University of Wisconsin at Madison in 2001 and a bachelor’s degree in medical chemistry in 1990 from Beijing University, China.

Skip to content